Cytiva News

  1. Cytiva Opens Cell Culture Center Of Excellence In Massachusetts 11/9/2022

    Global life sciences leader Cytiva opened a new Cell Culture Center of Excellence at its Marlborough, Massachusetts location.

  2. Cytiva Expanding US Operations 7/13/2022

    The new chromatography resins manufacturing site is part of Cytiva and Pall Corporation’s 1.5 billion USD capacity expansion investment.

  3. Cytiva Attains Business Continuity Management System ISO Certification 1/11/2022

    The new ISO 22301:2019 certification covers methods and procedures for maintaining emergency response, crisis management, and business continuity capabilities, including communication, implementation, and continual improvement.

  4. Cytiva Acquires GoSilico To Strengthen Digital Capabilities In Bioprocessing 6/2/2021

    Global life sciences leader Cytiva has acquired the German scientific software maker GoSilico, in a move that will differentiate Cytiva as a premier partner in bioprocessing.

  5. Cytiva's Fibro PrismA Technology Accelerates mAb Purification In LifeArc's Covid-19 Research 10/8/2020

    Cytiva, a global life sciences leader, made Fibro PrismA, the first product based on its new protein A fiber chromatography technology, available commercially earlier this year. The new technology is already accelerating research for customers and collaborators, such as LifeArc.

  6. Rentschler Biotechnologie Expands European Manufacturing Capabilities With GE Healthcare Life Sciences Bioprocess Technologies 4/14/2015

    GE Healthcare Life Sciences a provider of tools, technologies and services to the biopharmaceutical manufacturing industry and Rentschler Biotechnologie GmbH, a leading contract manufacturing and development organization (CDMO) for biopharmaceuticals, announced recently a joint celebration to mark the handover of GE Healthcare’s 1000th ÄKTAprocess and the expansion of Rentschler’s biopharmaceutical manufacturing capabilities in Laupheim, Germany.

  7. GE Healthcare Life Sciences Named As Finalist For Four Bioprocess Industry Awards 10/3/2014

    GE Healthcare Life Sciences  announced recently that the company has been shortlisted as a finalist for four BioProcess International (BPI) Awards1.

  8. GE Healthcare Launches Xuri™ IL-2 Growth Factor For The Reliable Activation And Expansion Of T-lymphocytes 5/14/2014

    Xuri™ IL-2 is a dedicated cell therapy ancillary product for the ex vivo cultivation of T-lymphocytes. Xuri IL-2’s defined level of biological activity removes the need for revalidation of each lot and strongly improves reproducibility, thereby minimizing process development time and improving scale out capacity.

  9. Nanotherapeutics Selects GE Healthcare Life Sciences Technologies For Advanced Development And Manufacturing Center 1/22/2014

    GE Healthcare recently announced that biopharmaceutical company Nanotherapeutics, Inc. has selected GE Healthcare Life Sciences' FlexFactory biomanufacturing platform to perform a central role in its Advanced Development and Manufacturing (NANO-ADM) Center at Alachua, Florida, USA.

  10. GE Healthcare Life Sciences To Build KUBio Modular Biopharmaceutical Factory For JHL Biotech In China 9/25/2013

    GE Healthcare Life Sciences, a business unit of GE Healthcare, and JHL Biotech, a provider of biopharmaceutical process development and manufacturing services, recently announced that a KUBio™ modular biopharmaceutical factory will be built in China for JHL Biotech.